{loadposition link_supportresistance}

The depositary for the tender offer has advised Johnson & Johnson that, as of the expiration of the initial offering period, a total of about 17.74 million shares of Cougar Biotechnology common stock were validly tendered and not withdrawn, representing about 84.4% of the outstanding shares of Cougar Biotechnology common stock.

The depositary has also advised Johnson & Johnson that it has received commitments to tender about 2.00 million additional shares under the guaranteed delivery procedures described in the offer.

Johnson & Johnson also announced that it is commencing through Kite Merger Sub Inc. a subsequent offering period of its tender offer to acquire all remaining shares of Cougar Biotechnology common stock. This subsequent offering period will expire on July 9, 2009, unless extended.

Any shares validly tendered during this subsequent offering period will be accepted immediately for payment, and tendering shareholders will thereafter promptly be paid $43.00 in cash for each share of Cougar Biotechnology common stock tendered, without interest and less any required withholding taxes.

{loadposition link_nowtime}